May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combination Arginyl-Glutamine (Arg-Gln) Dipeptide and Docosahexaenoic Acid (DHA) Promote Early Vascular Regrowth Following Hyperoxia Exposure and Reduce Preretinal Neovascularization in the Oxygen-Induced Retinopathy (OIR) Model
Author Affiliations & Notes
  • M. B. Grant
    University of Florida, Gainesville, Florida
    Pharmacology and Therapeutics,
  • L. C. Shaw
    University of Florida, Gainesville, Florida
    Pharmacology and Therapeutics,
  • N. Sengupta
    University of Florida, Gainesville, Florida
    Pharmacology and Therapeutics,
  • J. Neu
    University of Florida, Gainesville, Florida
    Pediatrics,
  • Footnotes
    Commercial Relationships  M.B. Grant, None; L.C. Shaw, None; N. Sengupta, None; J. Neu, None.
  • Footnotes
    Support  NIH1R01 EY07739, NIH R01EY12601 and the Juvenile Diabetes Research Foundation Grant 4-2000-847
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2630. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. B. Grant, L. C. Shaw, N. Sengupta, J. Neu; Combination Arginyl-Glutamine (Arg-Gln) Dipeptide and Docosahexaenoic Acid (DHA) Promote Early Vascular Regrowth Following Hyperoxia Exposure and Reduce Preretinal Neovascularization in the Oxygen-Induced Retinopathy (OIR) Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2630. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Retinopathy of prematurity (ROP) is the major cause of blindness in children. Supplementation with arginine, glutamine or DHA, a major omega-3 fatty acid, results in improved clinical outcomes in premature infants. Previously, we showed that Arg-Gln administered IP inhibits development of abnormal pre-retinal neovascularization in the OIR model (Neu, et al, IOVS, 2006). In this study we examined the protective effect of oral administration of Arg-Gln alone and in combination with DHA in pups undergoing the OIR model.

Methods: : Nursing dams and pups were returned to normal room air on P12 and gavaged twice daily with: Arg-Gln, DHA, Arg-Gln + DHA or vehicle (P12-P17). Normoxic pups were treated in an identical manner. On P17 the pups were perfused with FITC-labeled dextran. One eye was embedded in paraffin, cross-sectioned and H&E stained for analysis of pre-retinal neovascularization. The retina from the second eye underwent microscopic analysis for measurement of intra-retinal vascular density (P17) (central, mid and peripheral retina) to assess vascular regrowth.

Results: : The Arg-Gln dipeptide gave the greatest reduction in pre-retinal neovascularization (65 ± 1%, P < 0.001) compared to DHA (55 ± 2%, P < 0.001) or a combination of both (33 ± 2%, P < 0.001) relative to vehicle. All test compounds dramatically reduced the area of vaso-obliteration assessed in P17 pups (Arg-Gln: 4.8 ± 1.0%, P = 0.03; DHA: 3.6 ± 1.3%, P = 0.04; combination: 5.4 ± 0.7%, P = 0.02) when compared to vehicle (30.4 ± 7.9%). Intra-retinal vascular density was greatest in Arg-Gln groups of pups compared to the other treatment groups.

Conclusions: : Treatment with the Arg-Gln dipeptide also was superior to the combination (dipeptide with DHA) or DHA alone, however all treatments dramatically inhibited pre-retinal neovascularization, reduced vaso-obliteration and restored intra- vascular density in the OIR mouse model. These agents may serve as an effective nutraceutics for treatment of ROP.

Keywords: nutritional factors • retinal development • retinopathy of prematurity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×